Medicinova (MNOV) Reports Partnership with BARDA to Repurpose MN-166 (ibudilast) as Medical Countermeasure against Chlorine Gas-induced Lung Injury

Go back to Medicinova (MNOV) Reports Partnership with BARDA to Repurpose MN-166 (ibudilast) as Medical Countermeasure against Chlorine Gas-induced Lung Injury

Medicinova (MNOV) Doubles After-Hours on BARDA Deal to Repurpose MN-166

March 9, 2021 5:45 PM EST

Medicinova (NASDAQ: MNOV) surged 109% after-hours after the company partnered with BARDA to repurpose MN-166 to treat chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

... More